Researchers release baseline data from randomized colorectal cancer screening trial

December 03, 2002

A major trial is under way to determine the impact of single screening sigmoidoscopy on colorectal cancer incidence and mortality. Although the trial will take years to complete, outcomes from the recruitment and screening phases of the trial suggest that single screening sigmoidoscopy has a high cancer detection rate and is relatively safe and acceptable to patients. The findings appear in the December 4 issue of the Journal of the National Cancer Institute.

Scientists believe that colorectal cancers develop from adenomous polyps (abnormal growths) over a period of 10 to 15 years. Some have proposed that a single screening sigmoidoscopy around age 60 is a cost-effective approach to screening people for colorectal cancer. A sigmoidoscopy involves inserting a short, lighted tube into the rectum to check the colon wall for cancer and other abnormalities.

SCORE is a multicenter randomized controlled trial in Italy designed to measure the extent of reduction in colorectal cancer incidence and mortality achieved by a single screening sigmoidoscopy examination and to determine both the optimum age range for screening and how long the protective effect lasts.

Nereo Segnan, M.D., and his colleagues from the SCORE Working Group in Italy randomly assigned 34,292 people aged 55 to 64 to either an intervention group that was invited to undergo a sigmoidoscopy or a control group that was not invited for screening. Screenees who were found to have colorectal cancer or high risk polyps were referred for further testing with colonoscopy.

Of the people examined by sigmoidoscopy, 10.8% were found to have adenomas in the left side of the colon, the side closest to the rectum. Of the people who underwent further testing with colonoscopy, 15.5% were found to have adenomas in the right side of the colon. Colorectal cancers were found in 54 of the participants, a rate of 5.4 per 1,000. Furthermore, the procedures appeared relatively safe, with one perforation in nearly 10,000 sigmoidoscopy exams and one perforation in nearly 800 colonoscopies. There was also one hemorrhage requiring hospitalization after polypectomy (removal of a polyp). More than 80% of those screened described the associated pain as mild or less than expected.

"In conclusion, the baseline results from the SCORE trial show that sigmoidoscopy can be an acceptable and safe screening strategy for colorectal cancer," the authors write. "The high yield of advanced lesions and early colorectal cancer is consistent with the projected substantial impact of sigmoidoscopy screening on colorectal cancer incidence and mortality."
-end-
Contact: Nereo Segnan, Cancer Prevention Centre, Torino, Italy, +39 011 566 4560 or +39 335 755 3699 (no later than 2 pm EST), nereo.segnan@cpo.it

Segnan N, Senore C, Andreoni B, Aste H, Bonelli L, Crosta C, et al. Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"--SCORE. J Natl Cancer Inst 2002;94:1763-72.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Journal of the National Cancer Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.